Non Alcoholic Fatty Liver Disease Clinical Trial
Official title:
Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH
Recent epidemiological studies in France showed a high prevalence of obesity (14.5%) and its
strong increase in the last 20 years. Among the many complications associated with obesity,
liver complications (steatosis and steatohepatitis [NASH]) are among the most common.
Semaphorins were described in the early 1990. More than 20 types of these proteins have been
reported to date. These proteins were used for neural development. Since many functions have
also been described. The semaphorins are involved in numerous physiological or
physiopathological processes (cardiac morphogenesis, vascular growth, tumor progression), the
regulation of immune cells and liver fibrosis. Preliminary studies have allowed to show that
dendritic cells infiltrate adipose tissue and initiate the activation of T cells and
inflammation. Immune semaphorin are new players in the regulation of inflammation and immune
reactions.
The role of immune semaphorin in regulating inflammation in the two compartments (liver and
adipose tissue) could be a crucial step that could lead to more severe liver damage. Its
dysregulation could explain NASH injuries. The goal is to identify a new mode of regulation
of cellular homeostasis in the fatty liver disease. These factors may serve as diagnostic
markers or future therapeutic targets.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
| Completed |
NCT01277237 -
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04442620 -
Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity
|
N/A | |
| Completed |
NCT01999101 -
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
|
Phase 2 | |
| Completed |
NCT01327443 -
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
|
N/A | |
| Active, not recruiting |
NCT01482065 -
The Sleep, Liver Evaluation and Effective Pressure Study
|
N/A | |
| Completed |
NCT03135873 -
Mastiha Treatment for Obese With NAFLD Diagnosis
|
N/A | |
| Completed |
NCT02686476 -
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT01556113 -
Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
|
N/A | |
| Recruiting |
NCT06080386 -
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
|
||
| Terminated |
NCT02134522 -
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
|
N/A | |
| Completed |
NCT01553500 -
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
| Completed |
NCT05426382 -
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
|
N/A | |
| Completed |
NCT03300661 -
Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine
|
N/A | |
| Not yet recruiting |
NCT02178839 -
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
|
N/A | |
| Recruiting |
NCT02038387 -
Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)
|
N/A | |
| Completed |
NCT01874249 -
Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease
|
N/A | |
| Completed |
NCT01634048 -
The Effect of Protein-enriched Diet on Body Composition and Appetite
|
N/A | |
| Completed |
NCT01966627 -
Genetics of Fatty Liver Disease in Children
|
N/A | |
| Terminated |
NCT01842282 -
Amlexanox for Type 2 Diabetes and Obesity
|
Phase 2 |